Kazuyuki Matsuda
Education
INSEAD
Master of Business Administration - MBA, - 1996-12-01
The University of Tokyo
BA, Economics 1982-01-01 - 1986-01-01
INSEAD
MBA, -Work Experience
KORTUC INC.
Current
KORTUC INC.
Quadrac Co. Ltd
2016-11-01 - 2018-12-01
Quadrac Co. Ltd
Royal Gate Inc.
2015-11-01 - 2016-09-01
Royal Gate Inc.
Lyudia Inc (currently Ingenico Japan)
2013-08-01 - 2015-07-01
Lyudia Inc (currently Ingenico Japan)
Perseus Proteomics Inc.
2004-12-01 - 2008-12-01
Perseus Proteomics Inc.
Site Support Institute Inc (Site Management Organization, bought out by CMIC)
2002-06-01 - 2007-06-01
Site Support Institute Inc (Site Management Organization, bought out by CMIC)
HuBit Genomix Inc
2002-04-01 - 2003-02-01
HuBit Genomix Inc
Merrill Lynch
1997-04-01 - 2002-03-01
Merrill Lynch
Mitsubishi Corporation
1986-04-01 - 1995-01-01
Mitsubishi Corporation
Skills
Summary
KORTUC Inc is a biotech company developing a novel radiosensitizer to solve the fundamental limitation of conventional cancer radiotherapy and to improve its effectiveness. The technology has origin in Japan. Our drug consists mainly of hydrogen peroxide in a prefilled syringe format to inject directly into tumors right before radiotherapy. H2O2 makes radioresistant tumors radiosensitive. Our first clinical trial is ongoing for locally advanced/recurrent breast cancer as registrational Phase 2 study led by the UK Institute of Cancer Research in UK and India. We will soon start clinical trials for cervical and rectal cancers globally. We are also exploring another opportunity of our drug as immunostimulant in immunotherapy by activating anti-tumor immune response. Our HQ is in Palo Alto, the global heart of cancer radiotherapy ecosystem.
